Genmab Long Term Debt

Genmab (GMAB) currently reports a long-term debt of $5B as of June 2026. That compares with $130M in the prior-year period — up 3658.3% year over year. Use the charts on this page to explore Genmab's long-term debt history and peer comparisons.

Genmab's long-term debt increased from $130M to $5B — a 3658.3% year-over-year increase (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Genmab reported $5B in long-term debt as of June 2026. That compares with $130M in the prior-year period — up 3658.3% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current long-term debt of $5B, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Genmab, and consider following GMAB for alerts when major investors trade the stock.

Genmab is classified in the Healthcare sector. On long-term debt, it currently shows $5B. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing GMAB with unrelated industries.